Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of atezolizumab plus carboplatin-paclitaxel or carboplatin-nab-paclitaxel versus carboplatin-nab-paclitaxel in first-line stage IV squamous non-small cell lung cancer
2014-003208-59Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2015
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atezolizumab, carboplatin and paclitaxel in Pulmonary squamous cell carcinoma (3 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started Apr 2015; status: completed.
02
Drugs
atezolizumabcarboplatinpaclitaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2014-003208-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003208-59.